, Emrah Aksakal 2
, Uğur Aksu 2
, Hakan Altay 3
, Yıldırım Nesligül 4
, Ahmet Çelik 5
, Mehmet Ata Akil 6
, Lütfü Bekar 7
, Mustafa Gökhan Vural 8
, Rengin Çetin Güvenç 9
, Savaş Özer 10
, Dilek Ural 11
, Yüksel Çavuşoğlu 12
, Lale Tokgözoğlu 13
2Department of Cardiology, Erzurum Regional Training and Research Hospital; Erzurum-Turkey
3Department of Cardiology, Faculty of Medicine, Başkent University; İstanbul-Turkey
4Department of Cardiology, Faculty of Medicine, Kırıkkale University; Kırıkkale-Turkey
5Department of Cardiology, Faculty of Medicine, Mersin University; Mersin-Turkey
6Department of Cardiology, Faculty of Medicine, Dicle University; Diyarbakır-Turkey
7Department of Cardiology, Faculty of Medicine, Hitit University; Çorum-Turkey
8Department of Cardiology, Faculty of Medicine, Sakarya University; Sakarya-Turkey
9Department of Cardiology, Haydarpaşa Numune Training and Research Hospital; İstanbul-Turkey
10Department of Cardiology, Recep Tayyip Erdoğan University Training and Research Hospital; Rize-Turkey
11Department of Cardiology, Faculty of Medicine, Koç University; İstanbul-Turkey
12Department of Cardiology, Faculty of Medicine, Eskişehir Osmangazi University; Eskişehir-Turkey
13Department of Cardiology, Faculty of Medicine, Hacettepe University; Ankara-Turkey
Abstract
Objective: Heart failure (HF) is a progressive clinical syndrome. SELFIE-TR is a registry illustrating the overall HF patient profile of Turkey. Herein, all-cause mortality (ACM) data during follow-up were provided.
Materials and Methods: This is a prospective outcome analysis of SELFIE-TR. Patients were classified as acute HF (AHF) versus chronic HF (CHF) and HF with reduced ejection fraction (HFrEF), HF with mid-range ejection fraction, and HF with preserved ejection fraction and were followed up for ACM.
Results: There were 1054 patients with a mean age of 63.3±13.3 years and with a median follow-up period of 16 (7–17) months. Survival data within 1 year were available in 1022 patients. Crude ACM was 19.9% for 1 year in the whole group. ACM within 1 year was 13.7% versus 32.6% in patients with CHF and AHF, respectively (p<0.001). Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta blocker, and mineralocorticoid receptor antagonist were present in 70.6%, 88.2%, and 50.7%, respectively. In the whole cohort, survival curves were graded according to guideline-directed medical therapy (GDMT) scores ≤1 versus 2 versus 3 as 28% versus 20.2% versus 12.2%, respectively (p<0.001). Multivariate analysis of the whole cohort yielded age (p=0.009) and AHF (p=0.028) as independent predictors of mortality in 1 year.
Conclusion: One-year mortality is high in Turkish patients with HF compared with contemporary cohorts with AHF and CHF. Of note, GDMT score is influential on 1-year mortality being the most striking one on chronic HFrEF. On the other hand, in the whole cohort, age and AHF were the only independent predictors of death in 1 year.